Clinical Trial Update: Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study evaluating the combination of the Bcl-2 antisense oligonucleotide G3139 with paclitaxel in patients with recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• G3139 (oblimersen sodium) (oblimersen sodium)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Chicago | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED